CSU researchers maximize research through new NIH grants

November 29, 2016

The National Institute of General Medical Sciences, part of the National Institutes of Health, created a new way of funding science in 2015 that allows researchers the freedom to take on ambitious challenges and approach problems creatively, without many strings.

Three researchers from Colorado State University -- Lucas Argueso, Tai Montgomery and Tim Stasevich -- are among the 93 scientists across the country who recently received this innovative grant. The new model, Maximizing Investigators' Research Award, or MIRA, supports scientists' overall research programs through a single, unified grant.

The total amount received by the CSU team is $5.4 million over the next five years.

All three researchers are Boettcher Investigators, recipients of the Webb-Waring Biomedical Research Award from Boettcher Foundation, a program designed to support early-career scientists in Colorado who conduct significant, impactful research to advance knowledge and positively impact human health. One of the main goals of this award is to position new investigators to compete for major federal and private awards.

Lucas Argueso

Lucas Argueso is an associate professor in the Department of Environmental and Radiological Health Sciences in the College of Veterinary Medicine and Biomedical Sciences. His MIRA award will support a project that explores "Mechanisms and Phenotypic Consequences of Structural Genomic Variation."

Argueso will explore what causes the structure of genomes to change over time, and the consequences of these large-scale changes to living organisms. This includes studying how chromosomes can change in various processes in life, and how these changes can sometimes lead to disease. He plans to investigate the forces that cause chromosomes to break, and the cellular mechanisms that are responsible for preventing, surveying and repairing this damage.

Tai Montgomery

Tai Montgomery is an assistant professor in the College of Natural Sciences' Department of Biology. His project is titled, "Mechanism and Function of C. elegans microRNAs in Drug Resistance, Pathogen Defense, Fecundity and Development."

MicroRNAs, which are small, gene regulatory molecules within cells, are thought to have roles in many disease including cancer, as well as in drug resistance and in preventing bacterial and viral infections. Yet their specific functions are still unclear to scientists. Montgomery proposes to illuminate the genes and genetic networks under the control of microRNAs that affect development, drug resistance and pathogen defense. He will use the nematode species C. elegans for an animal model in seeking to understand these processes.

Tim Stasevich

Tim Stasevich is an assistant professor in the Department of Biochemistry and Molecular Biology, also in the College of Natural Sciences. His award will support a project titled "Quantifying Gene Regulation by Histone Modification with High Spatiotemporal Resolution In Vivo."

Changes in histones, the "spools" around which DNA is wrapped and packaged in cells, play a role in DNA transcription and are implicated in many diseases. It's unclear, though, exactly how histones contribute to gene expression - whether they actively control it, or just go along for the ride. Stasevich wants to answer this question by using his lab's newly developed microscopy techniques to image histone modification dynamics in single cells, in record-breaking spatio-temporal resolution.
-end-


Colorado State University

Related Drug Resistance Articles from Brightsurf:

New drug that can prevent the drug resistance and adverse effects
A research team in Korea is garnering attention for having developed an anticancer drug that could potentially prevent drug resistance.

New drug combinations help overcome resistance to immunotherapy
A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.

Drug overcomes chemotherapy resistance in ovarian cancer
In an international preclinical study, researchers found they could overcome chemotherapy resistance in clear cell ovarian cancer cell models using low doses of the drug 2-deoxy-D-glucose.

Engineers model mutations causing drug resistance
Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and 'second generation' approaches are needed.

Double success for University drug resistance research
Swansea University research into the threat posed by antifungal drug resistance has been highlighted in two prestigious international journals.

What fuels a 'domino effect' in cancer drug resistance?
KAIST researchers have identified mechanisms that relay prior acquired resistance to the first-line chemotherapy to the second-line targeted therapy, fueling a 'domino effect' in cancer drug resistance.

New flu drug drives drug resistance in influenza viruses
University of Wisconsin-Madison researchers examined the effects of baloxavir treatment on influenza virus samples collected from patients before and after treatment.

Resistance to last resort drug arose in patient over 3 weeks
French investigators have described development of resistance to one of the last resort therapies used to treat extremely drug-resistant Pseudomonas aeruginosa.

Cause of drug resistance in a drug resistance in intestinal tumors identified
Researchers clarify mechanisms that allow hard-to-treat cancers to develop, and have identified strategies that could lead to new therapies.

Engineered viruses could fight drug resistance
MIT biological engineers can program bacteriophages to kill different strains of E. coli by making mutations in the protein that the viruses use to bind to host cells.

Read More: Drug Resistance News and Drug Resistance Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.